Examination of the protein–protein interaction networks suggested that the correlation of TGFB2-related markers could potentially complement the PAM50 signature in the assessment of OS prognosis in breast cancer patients following validation of the TGFB2/EGFR/MYC protein associations in tumors. Here, TGFB2 is linked to breast carcinoma.